FIELD: medicine.
SUBSTANCE: method involves determining sensitivity index SI to interferon . SI is defined to be ratio of neutrophilic granulocyte activation index when treating with dose under study and neutrophilic granulocyte activation index without interferon. The IS value is calculated with respect to each of three therapeutic interferon doses: 3 mln IU, 6 mln IU and 15 mln IU. SI>1, minimum dose is to be prescribed on which cellular sensitivity has been observed. SI>1 being observed only on one of the doses, this very interferon dose is to be prescribed. SI≤1 being observed in all cases, interferon therapy is not to be advised.
EFFECT: enhanced effectiveness of treatment.
8 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ESTIMATING RENAL CARCINOMA PATIENT SENSITIVITY TO INTERFERON | 2005 |
|
RU2293988C2 |
| METHOD FOR PREDICTION OF INTERFERON SENSITIVITY IN PATIENTS SUFFERING RENAL CELL CARCINOMA | 2010 |
|
RU2437101C1 |
| METHOD FOR INDIVIDUAL PRESCRIPTION OF IMMUNOACTIVE PREPARATIONS IN TREATING INFECTIOUS-INFLAMMATORY DISEASES | 2011 |
|
RU2480760C2 |
| METHOD OF INTERFERON THERAPY EFFICIENCY PREDICTION IN KIDNEY CANCER | 2007 |
|
RU2338202C1 |
| METHOD FOR PREDICTING EARLY STAGE PYOSEPTIC POSTOPERATIVE COMPLICATIONS IN RENAL CELLULAR CANCER PATIENTS | 2004 |
|
RU2279082C2 |
| METHOD FOR PREDICTING THE RESULT OF ACUTE VIRAL HEPATITIS B | 2006 |
|
RU2315308C1 |
| METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS IN ACUTE RHINOSINUSITIS | 2010 |
|
RU2438134C1 |
| METHOD FOR DETERMINING AUTOLOGOUS ANTICANCER ACTIVITY OF BLOOD NEUTROPHILS IN ONCOLOGICAL DISEASES | 2020 |
|
RU2737495C1 |
| METHOD FOR CARRYING OUT INTERFERON THERAPY | 1995 |
|
RU2105566C1 |
| METHOD FOR DETERMINING ANTIBACTERIAL RESISTANCE OF HUMAN BODY | 2009 |
|
RU2431837C2 |
